Susceptibility patterns of bacterial isolates from intensive care and haematology/oncology patients in New Zealand

New Zealand Medical Journal

Volumn 110, Issue 1044, 1997, Pages 187-189

  Morris, Arthur J ^a,f   Bremner, David A ^b   Leng, Ron A ^c   Jones, Mark R ^d   Schousboe, Mona I ^e  

^a Gn Ln and Natl Women's Hospitals ^*  (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d WELLINGTON HOSPITAL   (New Zealand)

^e Christchurch Public Hospital   (New Zealand)

^f GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; CANCER CENTER; CROSS INFECTION; DRUG EFFECT; HOSPITAL SUBDIVISIONS AND COMPONENTS; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; NEW ZEALAND;

ANTI-BACTERIAL AGENTS; BACTERIA; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HOSPITAL UNITS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; NEW ZEALAND; ONCOLOGY SERVICE, HOSPITAL;

EID: 0031584238     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Emmerson AM, Enstone JE, Griffin M, Kelsey MC, Smyth ETM. The second national prevalence survey of infection in hospitals: overview of the results. J Hosp Infection 1996; 32: 175-90.
2. Vincent JL, Bihari D, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995; 274: 639-44.
3. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323-32.
4. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-15.
5. National Committee for Clinical Laboratory Standards. Methods for dilutional antimicrobial susceptibility tests for bacteria that grow aerobically, Third Edition; Approved Standard. NCCLS Document M7-A3, 1993. NCCLS, Villanova, Pennsylvania.
6. Verbist L. Epidemiology and sensitivity of 8625 ICU and haematology/oncology bacterial isolates in Europe. Scand J Infect Dis 1993; 91 (Suppl): 14-24.
7. Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-and aminoglycoside-resistant Enterococcus faecium bacteraemia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38: 1363-7.
8. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes of patients with bacteraemia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22: 663-70.
9. Smith JMB, Chambers ST. Klebsiella oxytoca revealing decreased susceptibility to extended spectrum β-lactams. J Antimicrob Chemother 1995; 36: 265-7.
10. Naumouski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 26: 1991-6.
11. Venezia RA, Scarano FJ, Preston KE, et al. Molecular epidemiology of an SHV-5 extended spectrum β-lactamase in Enterobacteriaceae isolated from infants in neonatal intensive care unit. Clin Infect Dis 1995; 21: 215-23.
12. Chambers ST. Which cephalosporin? NZ Med J 1992; 105: 498-500.